Pulsesight
  • About us
    • About us
    • Team
    • Investors
  • Technology
  • Pipeline
    • Pipeline
    • About AMD
    • PST-611
    • PST-809
  • News & Events
    • Press Releases
    • Events
    • In the News
  • Contact

Author: edgover

PulseSight Therapeutics Will Develop Next Generation Eye Gene Therapies

Posted on February 28, 2024January 18, 2026 by edgover
PulseSight Therapeutics Will Develop Next Generation Eye Gene Therapies
Posted in In the news

PulseSight unveils minimally invasive gene therapies for eye diseases

Posted on February 28, 2024January 18, 2026 by edgover
PulseSight unveils minimally invasive gene therapies for eye diseases
Posted in In the news

Posts navigation

Newer posts

Recent Posts

  • PulseSight completes Phase 1 dosing of gene therapy candidate PST-611 in dry AMD and geographic atrophy
  • PulseSight Completes Enrollment in Gene Therapy Trial
  • A New Attack on Blindness: PulseSight Completes Key Safety Trial for Novel Dry AMD Gene Therapy
  • Dosing completed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)
  • Targeting Iron in Dry AMD

Recent Comments

No comments to show.

Archives

  • January 2026
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • February 2025
  • January 2025
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • April 2024
  • March 2024
  • February 2024

Categories

  • In the news
  • Press release
CONTACT US
PRIVACY POLICY
DISCLAIMER

© 2026 PULSESIGHT THERAPEUTICS ALL RIGHTS RESERVED